[Skip to Content]
Navigation
Home > Medical Directory > Autoimmune Diseases > Lupus

Antibodies in Lupus

Author: Shelley Ensz. Scleroderma is highly variable. See Types of Scleroderma. Read Disclaimer
Overview
Antiphospholipid (aPL)
C Reactive Protein (CRP)
NKG2A
Scl-70 (topo-I) (ATA)

Overview of Lupus Antibodies

There are a wide variety of autoantibodies associated with lupus. Some of the antibodies are helpful in diagnosing the illness, while others are more useful in detecting disease activity or potential complications. (Also see: Autoimmune Diseases and Overview of Lupus)
Distinct antibody profile: a clue to primary antiphospholipid syndrome (PAPS) evolving into systemic lupus erythematosus (SLE)? The detection of a distinct subgroup of lupus-associated autoantibody in PAPS patients seems to be a hint to overt SLE disease, particularly in those patients with young age at diagnosis. PubMed, Clin Rheumatol, 2014 Jan 14. (Also see: Antiphospholipid Syndrome)
Autoantibodies and SLE-the threshold for disease. The current findings are summarized regarding the presence of SLE-associated antibodies in apparently healthy individuals, and provide opinions on what such discoveries might tell us about the roles of autoantibodies in the development of disease. PubMed, Nat Rev Rheumatol, 2013 Dec 3. (Also see: Autoantibodies)
Lots of autoantibodies equal systemic lupus erythematosus (SLE)? Autoantibodies may be found years before an autoimmune disease becomes clinically apparent and in patients with early SLE; no single antibody class or specificity is associated with progression to SLE. Arthritis Research & Therapy 2013, 15:102.

Antiphospholipid Antibodies (aPL)

Cigarette smoking, antiphospholipid antibodies (aPL) and vascular events (VE) in Systemic Lupus Erythematosus (SLE). Among ever regular smokers who were aPL positive, there was a strikingly high frequency of former VE and the underlying mechanisms and temporality between smoking, aPL and VE need further investigations. PubMed, Ann Rheum Dis, 2014 Apr 1. (Also see: Antiphospholid Syndrome)

C Reactive Protein (Anti-CRP)

Anti-CRP antibodies in systemic lupus erythematosus. Anti-CRP autoantibodies, which are found in 35 to 40% of SLE patients, increase the cardiovascular risk by interacting with the monomeric (degraded) form of CRP. PubMed, Joint Bone Spine.

NKG2A Antibodies

Anti-NKG2A autoantibodies in a patient with systemic lupus erythematosus (SLE). NKG2A autoantibodies are rare, but when they occur they may contribute to the pathogenesis by increasing the killing of cells and the release of autoantigens. PubMed, Rheumatology, 2013 Jul 3.

Scl-70 (topo-I) (ATA)

Anti-Scl-70 (topo-I) antibodies (ATA) in Systemic Lupus Erythematosus (SLE): Myth or reality? Given that SLE is approximately 100 times more prevalent than systemic sclerosis (SSc), the number of ATA positive SLE patients is 2-3 orders of magnitude greater than the prevalence of ATA in SSc. Autoimmun Rev, 2010 Jun 22.(Also see: Overview of Lupus)
 
Go to Treatments for Lupus
 

SCLERO.ORG is operated by the International Scleroderma Network, which is a full-service U.S. nonprofit 501(c)(3) established in 2002. We provide stellar worldwide research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. Donate or Shop Now.

Questions? Post a message in Sclero Forums or email us directly at isn@sclero.org. Or call our Scleroderma Hotline (English only), Toll Free in U.S. 1-800-564-7099 or Direct at 1-952-831-3091. Ask for our Welcoming Email.

Our headquarters postal mailing address is: International Scleroderma Network (ISN), 7455 France Ave So #266, Edina, MN 55435-4702, United States.

The most important thing in the world to know about scleroderma...is sclero.org!
Home   Medical   News   Sclero Forums   Support   Translations  Donate or Shop
Copyright 1998-2014, International Scleroderma Network. AKA Scleroderma from A to Z and SCLERO.ORG. All Rights Reserved.